logo

For the Inventor, By the Inventor

Wiesbaden, Germany

Hans Michael Jennewein

This inventor holds 18 USPTO granted patents. Top assignees: Boehringer Ingelheim Pharma Kg, Boehringer Ingelheim Kg, Boehringer Ingelheim Pharma Gmbh & Co Kg. Active years: 1983-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Michael Jennewein. Retrieved from https://idiyas.com/inventor/hans-michael-jennewein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 59(Granted Patents)


Location History:

  • Walluf, DE (1983 - 1987)
  • Wiesbaden, DE (2000 - 2005)

Company Filing History:

goldMedal13 out of 149 
 
Boehringer Ingelheim Pharma Kg
 patents
silverMedal3 out of 197 
 
Boehringer Ingelheim Kg
 patents
bronzeMedal1 out of 194 
 
Boehringer Ingelheim Pharma Gmbh & Co Kg
 patents
4. 1 out of 9 
 
C. H. Boehringer Sohn
 patents

Years Active: 1983-2005

Loading Chart...
18 patents (USPTO):Explore Patents
1. 6855713 - Benzimidazole derivatives, a process for their manufacture and use as a medicine (2005-02-15),
2. 6780863 - Bis-basic compounds with tryptase-inhibitory activity (2004-08-24),
3. 6656956 - Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions (2003-12-02),
4. 6576669 - Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes (2003-06-10),
5. 6528491 - Pyranoside derivatives (2003-03-04),
6. 6512000 - Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity (2003-01-28),
7. 6489359 - Sulphoxybenzamides (2002-12-03),
8. 6413990 - Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity (2002-07-02),
9. 6407130 - Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity (2002-06-18),
10. 6365584 - Arylysulphonamide-substituted benzimidazoles having tryptase-inhibiting activity (2002-04-02),
11. 6288277 - Benzylamine and phenylethylamine derivatives, processes for preparing the same and their use as medicaments (2001-09-11),
12. 6265612 - Benzamidine derivatives and the use thereof as medicaments with LTB4-antagonistic effect (2001-07-24),
13. 6197824 - Benzamidine derivatives and the use thereof as medicaments with LTB4-antagonistic effect (2001-03-06),
14. 6197753 - Pyranoside derivatives (2001-03-06),
15. 6133479 - Phenylethylamine derivatives, processes for preparing them and their use (2000-10-17),

Title: The Innovative Journey of Hans Michael Jennewein

Introduction: Hans Michael Jennewein, a prolific inventor based in Wiesbaden, DE, has made significant contributions to the field of medicine through his 18 patents and groundbreaking inventions.

Latest Patents:

1. Benzimidazole derivatives, a process for their manufacture and use as a medicine: Jennewein's recent patent revolves around benzimidazole derivatives with trypsin-inhibiting action, showcasing his expertise in medicinal chemistry.

2. Bis-basic compounds with tryptase-inhibitory activity: Another notable invention by Jennewein, highlighting his focus on developing compounds with therapeutic benefits.

Career Highlights: Jennewein has worked with renowned pharmaceutical companies like Boehringer Ingelheim Pharma KG and Boehringer Ingelheim KG, where he honed his skills and brought his innovative ideas to life in the healthcare sector.

Collaborations: Throughout his career, Jennewein has collaborated with talented individuals such as Ralf Anderskewitz and Franz Birke, fostering a culture of innovation and teamwork in his research endeavors.

Conclusion: Hans Michael Jennewein's remarkable journey as an inventor underscores his passion for advancing medicine through cutting-edge inventions. His patents and collaborations exemplify his dedication to pushing the boundaries of scientific discovery in the pursuit of improving healthcare outcomes for all.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…